Short-term Outcome of Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Short term mortality rate
研究概览
简要总结
Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.
详细描述
Assessment of the 30-day mortality and major complications as well as the tumor size changes of the patients undergoing ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma. This is a prospective non randomized trial carried out at the Ribat University Hospital between April 2017 to March 2018.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Review and sign informed consent;
- •Between 15 and 80 years of age at time of trial enrollment;
- •Documented pathological and/or radiological diagnosis of hepatocellular carcinoma;
- •Radiologically documented tumor size of > 5 centimeters;
- •Radiologically documented liver cirrhosis.
排除标准
- •American Anesthesia Association (ASA) Class IV or V and/or any contraindications to general anesthesia;
- •Uncontrollable ascites;
- •Deep persistent jaundice;
- •Hepatic encephalopathy;
- •Coagulopathy;
- •Severe thrombocytopenia;
- •Unable or unwilling to attend follow up visits and examinations;
- •Other associated surgical procedure;
研究组 & 干预措施
Devascularization
Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
干预措施: HALED (Procedure)
结局指标
主要结局
Short term mortality rate
时间窗: 30 day
Percentage of patients' postoperative deaths
次要结局
- Tumor response rate according to mRECIST criteria.(30 days)
- Short term major complications' rate(30 days)
研究者
Osama Mohamed Elsanousi
Associate Professor of Surgery
The National Ribat University